

## **Minerva at a glance**

Minerva Neurosciences is developing a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. This portfolio includes four compounds with mechanisms of action that we believe are first-in-class.

Our mission is to develop differentiated therapies that address significant unmet needs in the treatment of schizophrenia, insomnia and mood disorders, major depressive disorder and Parkinson's disease. Toward that end, we are applying the knowledge, insights and expertise that our team has accumulated over more than 30 years working in clinical facilities and on pre-clinical and clinical research projects.

We are driven by the recognition of the profound human impact, extensive demographic reach and serious financial burden of the diseases we are targeting, and we invite you to visit our website at [www.minervaneurosciences.com](http://www.minervaneurosciences.com) to learn more about our ongoing efforts in the field of central nervous system disorders.

## **Management Team**

Remy Luthringer, Ph.D., President and Chief Executive Officer

Geoff Race, Executive Vice President, Chief Financial Officer, and Chief Business Officer

Joseph Reilly, Senior Vice President and Chief Operating Officer

Fred Ahlholm, Senior Vice President and Chief Accounting Officer

Mark Levine, Senior Vice President, General Counsel and Secretary

## **Investor Contact**

William Boni, Vice President, Investor Relations and Corporate Communications

## **Company Information**

Minerva Neurosciences, Inc. (Nasdaq: NERV)

1601 Trapelo Road

Waltham, MA 02451

(617) 600-7373

## Transfer Agent

Computershare Trust Company, Inc.

[www.computershare.com](http://www.computershare.com)

US Phone: +1 877 373 6374

International Phone: +1 781 575 2879

## Product Portfolio

Product Candidates	Targeted Diseases	Mechanisms of Action
<b>MIN-101</b>	Schizophrenia	<ul style="list-style-type: none"><li>● 5-HT<sub>2A</sub> antagonist</li><li>● Sigma<sub>2</sub> antagonist</li></ul>
<b>MIN-202</b>	Primary Insomnia Major Depressive Disorder	<ul style="list-style-type: none"><li>● Selective Orexin<sub>2</sub> antagonist</li></ul>
<b>MIN-117</b>	Major Depressive Disorder	<ul style="list-style-type: none"><li>● 5-HT<sub>1A</sub></li><li>● 5HT transporter<ul style="list-style-type: none"><li>● Alpha-1a, b</li></ul></li><li>● Dopamine transporter</li><li>● 5-HT<sub>2A</sub> antagonist</li></ul>
<b>MIN-301</b>	Parkinson's Disease	<ul style="list-style-type: none"><li>● Neuregulin 1<math>\beta</math>1 activating ErbB4</li></ul>